This is the post-IPO drug pipeline image for Camp4 Therapeutics.

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) just came public in October and the stock’s quiet period has now ended. This means that analysts who work for firms in the underwriting syndicate are now free to issue their formal ratings. After starting trading for its 6.820 million shares priced at $11.00 per share, its first-day closing price of $10.72 had drifted down to $8.22 ahead of the quiet-period expiration. Now the analyst coverage has shares back up over 10% and at $9.40 it has big “implied analyst upside” but is still trading as a busted IPO as it is below the priced deal.

So, now that all of the introduction is out of the way — is CAMP4 a Buy, Sell, Hold or Avoid?

CAMP4 is developing a pipeline of regulatory RNA-targeting therapeutics to restore healthy protein levels targeting multiple genetic diseases. The company’s an initial focus is on metabolic and central nervous system diseases; and its expansion areas on its pipeline page are listed as skeletal muscle, heart, and the immune system.

One confusion about CAMP4 that may distract investors until the company is better know is that the “CAMP” stock ticker was the same ticker used for CalAmp which filed for bankruptcy and went private earlier in 2024. These two companies share nothing else in common.

BIOMARIN PACT

At the start of October, CAMP4 entered into a new research collaboration with BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The research pact is targeting advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences as key elements controlling gene expression.

The press release from both companies showed that the terms grant BioMarin the right to select two targets identified by CAMP4’s RAP Platform to advance into clinical development. Financial terms were not fully disclosed on the BioMarin press release, but CAMP4 showed it would receive an upfront payment and was eligible for additional milestones and tiered royalties

ANALYST SUMMARIES

Tactical Bulls always reminds investors and its readers that no single analyst report should ever be the sole basis to buy or sell a stock. That decision to buy or sell, or hold or short sell, is up to each investor and the decision should be made with a financial advisor. And there are of course no assurances that any of the price predictions and the scenarios that back the calls up will actually come to fruition.

So, here are four analyst calls that have so far been issued on CAMP4.

J.P. Morgan started CAMP4 as Overweight with a $23 price target. The firm sees its ASO RNA Actuator Platform offering a potential to systematically restore the expression of specific proteins due to genetic haploinsufficiency. It also sees it becoming constructive with a potential de-risk to clinical study data readouts in both Q1-2025 and H2-2025.

Piper Sandler started CAMP4 as Overweight with a $18 price target, noting that CAMP4 now has enough pro forma cash ($79 million or so) to fund its operations into Q2-2026.

Leerink Partners started CAMP 4 as Outperform with a $17 price target.

William Blair started CAMP4 as Outperform, but no price target data was immediately available.

DISCLAIMER

None of the views in this report are intended to be interpreted as investment advice nor do they constitute a recommendation to buy or sell CAMP4 shares. Tactical Bulls does not have any formal ratings nor price targets on this company. Any decision to buy, sell, hold, short or avoid is the responsibility of each investor individually. Those decisions should also be made with a financial advisor.

Please understand that analysts often have no better access to information nor any better insight than other sophisticated investors. There are no assurances that analyst price target, even with 50% to 100% implied upside, will come to fruition.

THE STOCK REACTION

Shares of CAMP4 were trading up over 14% at $9.42 late on Tuesday after the analyst reports. It is not highly unusual to see more predicted upside than the traditional 8% to 12% upside in blue chip analyst Buy and Outperform ratings. These targets are closer to double the current share price.

Please keep in mind that outside of research monies coming in CAMP4 will likely not have any revenues to speak of for quite some time. And even then, that assumes its pipeline pays off with safe and effective products down the road.